Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir
Author:
Affiliation:
1. Clinical Virology, Gilead Sciences, Inc , Foster City, California , USA
2. Clinical Pharmacology, Gilead Sciences, Inc , Foster City, California , USA
3. Clinical Research, Gilead Sciences, Inc , Foster City, California , USA
Abstract
Funder
Gilead Sciences, Inc.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Immunology and Allergy
Link
https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiac364/46041619/jiac364.pdf
Reference21 articles.
1. Clinical targeting of HIV capsid protein with a long-acting small molecule;Link;Nature,2020
2. Absence of lenacapavir (GS-6207) phenotypic resistance in HIV gag cleavage site mutants and in isolates with resistance to existing drug classes;Margot;Antimicrob Agents Chemother,2021
3. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study;Margot;J Antimicrob Chemother,2022
4. Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients;Marcelin;J Antimicrob Chemother,2020
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Lenacapavir: A novel injectable HIV-1 capsid inhibitor;International Journal of Antimicrobial Agents;2024-01
2. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study;The Lancet HIV;2024-01
3. Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants;The Journal of Infectious Diseases;2023-12-07
4. Discovery, Crystallographic Studies, and Mechanistic Investigations of Novel Phenylalanine Derivatives Bearing a Quinazolin-4-one Scaffold as Potent HIV Capsid Modulators;Journal of Medicinal Chemistry;2023-12-06
5. Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA;Antiviral Therapy;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3